GLP-1
FDA approves Novo Nordisk’s Victoza for children with type 2 diabetes
June 18, 2019Manufacturing and Production GLP-1, Novo Nordisk, Victoza, diabetes, liraglutide
The FDA has approved Novo Nordisk’s Victoza (liraglutide) for paediatric patients aged 10 years and older with type 2 diabetes. …
Novo Nordisk’s oral diabetes drug safe and effective
June 12, 2019Research and Development GLP-1, Novo Nordisk, diabetes, pharma, samgalutide
Novo Nordisk’s oral diabetes drug semaglutide is safe for those at high risk of cardiovascular complications, according to the results …
Study supports GLP-1 agonists for weight loss
January 10, 2012Research and Development, Sales and Marketing GLP-1, Novo Nordisk, Sanofi, diabetes, lilly
An independent study by academics has concluded that GLP-1 agonist drugs help patients to lose weight – with the effect …
GSK diabetes drug fails head-to-head against Victoza
November 16, 2011Sales and Marketing GLP-1, Victoza, albiglutide, diabetes
GlaxoSmithKline’s long-acting diabetes drug albiglutide has failed in a head-to-head trial against Novo Nordisk’s Victoza. Albiglutide is an injectable glucagon-like …
Byetta approved for use with insulin
October 19, 2011Amylin, GLP-1, diabetes, lilly
The FDA has approved the use of Lilly and Amylin’s diabetes treatment Byetta as an add-on therapy to insulin glargine.The …
Fresh scrutiny for new diabetes drugs
September 15, 2011Sales and Marketing Byetta, GLP-1, Januvia, Merck, Novo Nordisk, Victoza, diabetes
Merck’s Januvia and Lilly’s Byetta face renewed safety questions this week as the European Association for the Study of Diabetes …
Future of Roche diabetes trial uncertain
September 14, 2010Research and Development GLP-1, Roche, taspoglutide
Roche has admitted it does not know when phase III trials of the investigational type II diabetes drug taspoglutide will …
Lixisenatide scores in phase III trial
April 15, 2010Research and Development GLP-1, Lixisenatide, diabetes
Sanofi-Aventis’ novel, once-daily diabetes treatment lixisenatide has successfully met its phase III glucose blood level and glycaemic control endpoints. The …
Roche diabetes trial proves promising
February 11, 2010Research and Development GLP-1, Roche, diabetes, taspoglutide
Phase III results for Roche’s once-weekly injectable drug taspoglutide have shown a positive effect on reducing blood glucose compared with …
Pancreatitis concerns take shine off Victoza approval
January 28, 2010Sales and Marketing GLP-1, Novo Nordisk, Victoza
The FDA has approved Novo Nordisk’s Victoza a new once-daily injection for patients with type II diabetes. The drug will …
Victoza pill trial begins
January 19, 2010Research and Development, Sales and Marketing GLP-1, Novo Nordisk, Victoza, diabetes, type II
A promising new diabetes treatment which can be taken as a pill instead of as an injection has just begun …
